Catheter-Related Bloodstream Infection Trends and Forecast
The future of the global catheter-related bloodstream infection market looks promising with opportunities in the coagulase-negative staphylococcus, yeast, pseudomonas, s. aureus, enterococci and streptococci, and enteric gram-negative bacilli markets. The global catheter-related bloodstream infection market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are increasing frequency of diseases acquired in hospitals, rise in the quantity of invasive medical treatments, as well as, growing incidence of chronic illnesses worldwide and an aging population in many parts of the world.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Catheter-Related Bloodstream Infection by Segment
The study includes a forecast for the global catheter-related bloodstream infection by drug class, treatment, source of infection, distribution channel, and region.
Catheter-Related Bloodstream Infection Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:
• Cefazoline
• Vancomycin
• Cloxacillin
• Daptomycin
• Others
Catheter-Related Bloodstream Infection Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:
• Antibiotic Lock Therapy
• Anti-Microbial Agents
Catheter-Related Bloodstream Infection Market by Source of Infection [Shipment Analysis by Value from 2018 to 2030]:
• Coagulase-Negative Staphylococcus
• Yeast
• Pseudomonas
• S.aureus
• Enterococci & Streptococci
• Enteric Gram-Negative Bacilli
• Others
Catheter-Related Bloodstream Infection Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Catheter-Related Bloodstream Infection Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Catheter-Related Bloodstream Infection Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies catheter-related bloodstream infection companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the catheter-related bloodstream infection companies profiled in this report include-
• Pfizer
• Citius Pharmaceuticals
• Glenmark Pharmaceuticals
• Geistlich Pharma
• CorMedix
• TauroPharm
• Fresenius
• Novartis
• Teva Pharmaceuticals
• Eli Lilly & Company
Catheter-Related Bloodstream Infection Market Insights
Lucintel forecasts that antibiotic lock therapy is expected to witness the higher growth over the forecast period.
Within this market, coagulase-negative staphylococcus is expected to witness the highest growth.
North America will remain the largest region over the forecast period due to growing demand for catheter insertion.
Features of the Global Catheter-Related Bloodstream Infection Market
Market Size Estimates: Catheter-related bloodstream infection market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Catheter-related bloodstream infection market size by drug class, treatment, source of infection, distribution channel, and region in terms of value ($B).
Regional Analysis: Catheter-related bloodstream infection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different drug class, treatment, source of infection, distribution channel, and regions for the catheter-related bloodstream infection market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the catheter-related bloodstream infection market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for catheter-related bloodstream infection market?
Answer: The global catheter-related bloodstream infection market is expected to grow with a CAGR of 5.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the catheter-related bloodstream infection market?
Answer: The major drivers for this market are increasing frequency of diseases acquired in hospitals, rise in the quantity of invasive medical treatments, as well as, growing incidence of chronic illnesses worldwide and an aging population in many parts of the world.
Q3. What are the major segments for catheter-related bloodstream infection market?
Answer: The future of the global catheter-related bloodstream infection market looks promising with opportunities in the coagulase-negative staphylococcus, yeast, pseudomonas, s. aureus, enterococci and streptococci, and enteric gram-negative bacilli markets.
Q4. Who are the key catheter-related bloodstream infection market companies?
Answer: Some of the key catheter-related bloodstream infection companies are as follows:
• Pfizer
• Citius Pharmaceuticals
• Glenmark Pharmaceuticals
• Geistlich Pharma
• CorMedix
• TauroPharm
• Fresenius
• Novartis
• Teva Pharmaceuticals
• Eli Lilly & Company
Q5. Which catheter-related bloodstream infection market segment will be the largest in future?
Answer: Lucintel forecasts that antibiotic lock therapy is expected to witness the higher growth over the forecast period.
Q6. In catheter-related bloodstream infection market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to growing demand for catheter insertion.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the catheter-related bloodstream infection market by drug class (cefazoline, vancomycin, cloxacillin, daptomycin, and others), treatment (antibiotic lock therapy and anti-microbial agents), source of infection (coagulase-negative staphylococcus, yeast, pseudomonas, s.aureus, enterococci & streptococci, enteric gram-negative bacilli, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Catheter-Related Bloodstream Infection Market, Catheter-Related Bloodstream Infection Market Size, Catheter-Related Bloodstream Infection Market Growth, Catheter-Related Bloodstream Infection Market Analysis, Catheter-Related Bloodstream Infection Market Report, Catheter-Related Bloodstream Infection Market Share, Catheter-Related Bloodstream Infection Market Trends, Catheter-Related Bloodstream Infection Market Forecast, Catheter-Related Bloodstream Infection Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.